Flu-Bu-Mel Based Conditioning Regimen for Patients With Lymphoid Malignancies Undergoing Allo-HSCT
Primary Purpose
Lymphoid Neoplasm
Status
Recruiting
Phase
Phase 2
Locations
China
Study Type
Interventional
Intervention
Flu-Bu-Mel-E
Sponsored by

About this trial
This is an interventional treatment trial for Lymphoid Neoplasm
Eligibility Criteria
Inclusion Criteria:
- lymphoid malignancies
- donor available: HLA matched sibling, unrelated donor or haplo-identical related donor.
- patients with ECOG <3
Exclusion Criteria:
- inform consent not provided
- ECOG >=3
- poor liver function (enzyme >2N or bilirubin >2N)
- poor renal function (Scr >2N)
- poor cardiac function (EF <45%)
Sites / Locations
- Blood & Marrow Transplantation Center, RuiJin HospitalRecruiting
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
treatment arm
Arm Description
treatment arm
Outcomes
Primary Outcome Measures
disease-free survival
event defined as disease progression, relapse or death of any causes
Secondary Outcome Measures
Overall survival
event defined as death of any causes
Non relapse morality
event defined as death of any causes except for disease progression or relapse
Relapse
event defined as disease progression or relapse
GVHD-free or relapse-free survival
event defined as disease progression or relapse, death of any cause, grade III-IV aGVHD or moderate to severe cGVHD
Full Information
NCT ID
NCT04897139
First Posted
May 19, 2021
Last Updated
October 21, 2023
Sponsor
Shanghai Jiao Tong University School of Medicine
1. Study Identification
Unique Protocol Identification Number
NCT04897139
Brief Title
Flu-Bu-Mel Based Conditioning Regimen for Patients With Lymphoid Malignancies Undergoing Allo-HSCT
Official Title
Phase II Clinical Trial of Flu-Bu-Mel-E (Fludarabine, Busulfan, Melphalan and Etoposide) as Conditioning Regimen for Patients With Lymphoid Malignancies Undergoing Allogeneic Stem Cell Transplantation
Study Type
Interventional
2. Study Status
Record Verification Date
October 2023
Overall Recruitment Status
Recruiting
Study Start Date
January 1, 2021 (Actual)
Primary Completion Date
June 1, 2024 (Anticipated)
Study Completion Date
December 1, 2024 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Shanghai Jiao Tong University School of Medicine
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
In this phase II clinical trial, we evaluate the efficacy and feasibility of conditioning regimen of fludarabine 150mg/m2, busulfan 9.6mg/kg, melphalan 100mg/m2 and etoposide 800mg/m2 in patients with lymphoid malignancies.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Lymphoid Neoplasm
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
23 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
treatment arm
Arm Type
Experimental
Arm Description
treatment arm
Intervention Type
Drug
Intervention Name(s)
Flu-Bu-Mel-E
Intervention Description
Fludarabine 150mg/m2, busulfan 6.4mg/kg, melphalan 100mg/m2 and etoposide 600mg/m2
Primary Outcome Measure Information:
Title
disease-free survival
Description
event defined as disease progression, relapse or death of any causes
Time Frame
1 year after allo-HSCT
Secondary Outcome Measure Information:
Title
Overall survival
Description
event defined as death of any causes
Time Frame
1 year after allo-HSCT
Title
Non relapse morality
Description
event defined as death of any causes except for disease progression or relapse
Time Frame
1 year after allo-HSCT
Title
Relapse
Description
event defined as disease progression or relapse
Time Frame
1 year after allo-HSCT
Title
GVHD-free or relapse-free survival
Description
event defined as disease progression or relapse, death of any cause, grade III-IV aGVHD or moderate to severe cGVHD
Time Frame
1 year after allo-HSCT
10. Eligibility
Sex
All
Minimum Age & Unit of Time
16 Years
Maximum Age & Unit of Time
60 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
lymphoid malignancies
donor available: HLA matched sibling, unrelated donor or haplo-identical related donor.
patients with ECOG <3
Exclusion Criteria:
inform consent not provided
ECOG >=3
poor liver function (enzyme >2N or bilirubin >2N)
poor renal function (Scr >2N)
poor cardiac function (EF <45%)
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Jiong Hu
Phone
86-21-64370045
Ext
601818
Email
hj10709@rjh.com.cn
First Name & Middle Initial & Last Name or Official Title & Degree
Jieling Jiang
Phone
86-21-64370045
Ext
601818
Email
jjl12223@rjh.com.cn
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Jiong HU
Organizational Affiliation
Ruijin Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
Blood & Marrow Transplantation Center, RuiJin Hospital
City
Shanghai
ZIP/Postal Code
200025
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jiong HU, M.D.
Phone
86-21-64370045
Ext
601818
Email
hj10709@rjh.com.cn
12. IPD Sharing Statement
Learn more about this trial
Flu-Bu-Mel Based Conditioning Regimen for Patients With Lymphoid Malignancies Undergoing Allo-HSCT
We'll reach out to this number within 24 hrs